enGene Therapeutics Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
1.740
-0.010 (-0.57%)
At close: Jun 17, 2026, 4:00 PM EDT
1.755
+0.015 (0.86%)
After-hours: Jun 17, 2026, 6:57 PM EDT
enGene Therapeutics Employees
As of October 31, 2025, enGene Therapeutics had 82 total employees, including 81 full-time and 1 part-time employees. The number of employees increased by 25 or 43.86% compared to the previous year.
Employees
82
Change (1Y)
25
Growth (1Y)
43.86%
Revenue / Employee
n/a
Profits / Employee
-$1,546,951
Market Cap
116.56M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Oct 31, 2025 | 82 | 25 | 43.86% | 81 | 1 |
| Oct 31, 2024 | 57 | 24 | 72.73% | 56 | 1 |
| Oct 31, 2023 | 33 | - | - | 31 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Alps Group | 93 |
| Agenus | 81 |
| PepGen | 56 |
| Pyxis Oncology | 56 |
| Oncolytics Biotech | 29 |
| Jyong Biotech | 27 |
| Spero Therapeutics | 25 |
| Coya Therapeutics | 8 |
ENGN News
- 2 days ago - enGene Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
- 2 days ago - enGene Therapeutics Earnings release: Q2 2026 - Filings
- 2 days ago - enGene Therapeutics Quarterly report: Q2 2026 - Filings
- 8 days ago - enGene Therapeutics Transcript: AGM 2026 - Transcripts
- 5 weeks ago - enGene Therapeutics Proxy statement: Proxy filing - Filings
- 5 weeks ago - enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 5 weeks ago - enGene Therapeutics Transcript: Study result - Transcripts
- 5 weeks ago - enGene Therapeutics Slides: Study result - Filings